Arcutis Biotherapeutics I... (ARQT)
Arcutis Biotherapeutics Statistics
Share Statistics
Arcutis Biotherapeutics has 118.64M shares outstanding. The number of shares has increased by 1.8% in one year.
| Shares Outstanding | 118.64M |
| Shares Change (YoY) | 1.8% |
| Shares Change (QoQ) | 0.13% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 104.38M |
| Failed to Deliver (FTD) Shares | 322 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 20.22M, so 17.27% of the outstanding shares have been sold short.
| Short Interest | 20.22M |
| Short % of Shares Out | 17.27% |
| Short % of Float | 19.63% |
| Short Ratio (days to cover) | 9.21 |
Valuation Ratios
The PE ratio is -12.03 and the forward PE ratio is -15.55. Arcutis Biotherapeutics's PEG ratio is 0.17.
| PE Ratio | -12.03 |
| Forward PE | -15.55 |
| PS Ratio | 8.57 |
| Forward PS | 2.2 |
| PB Ratio | 10.7 |
| P/FCF Ratio | -15 |
| PEG Ratio | 0.17 |
Enterprise Valuation
Arcutis Biotherapeutics Inc. has an Enterprise Value (EV) of 340.45M.
| EV / Earnings | -2.43 |
| EV / Sales | 1.73 |
| EV / EBITDA | -3.11 |
| EV / EBIT | -2.65 |
| EV / FCF | -3.03 |
Financial Position
The company has a current ratio of 4.15, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.15 |
| Quick Ratio | 3.97 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 2.1 |
| Cash Flow / Debt | -33.16 |
| Interest Coverage | -4.73 |
Financial Efficiency
Return on equity (ROE) is -0.89% and return on capital (ROIC) is -80.16%.
| Return on Equity (ROE) | -0.89% |
| Return on Assets (ROA) | -0.4% |
| Return on Capital (ROIC) | -80.16% |
| Revenue Per Employee | $574,684.21 |
| Profits Per Employee | $-409,470.76 |
| Employee Count | 342 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 1.32 |
Taxes
| Income Tax | 647K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 58.73% in the last 52 weeks. The beta is 1.49, so Arcutis Biotherapeutics's price volatility has been higher than the market average.
| Beta | 1.49 |
| 52-Week Price Change | 58.73% |
| 50-Day Moving Average | 14 |
| 200-Day Moving Average | 11.38 |
| Relative Strength Index (RSI) | 53.83 |
| Average Volume (20 Days) | 2.32M |
Income Statement
In the last 12 months, Arcutis Biotherapeutics had revenue of 196.54M and earned -140.04M in profits. Earnings per share was -1.16.
| Revenue | 196.54M |
| Gross Profit | 177.41M |
| Operating Income | -128.4M |
| Net Income | -140.04M |
| EBITDA | -109.63M |
| EBIT | -128.4M |
| Earnings Per Share (EPS) | -1.16 |
Balance Sheet
The company has 71.33M in cash and 3.38M in debt, giving a net cash position of 67.95M.
| Cash & Cash Equivalents | 71.33M |
| Total Debt | 3.38M |
| Net Cash | 67.95M |
| Retained Earnings | -1.12B |
| Total Assets | 348.89M |
| Working Capital | 254.81M |
Cash Flow
In the last 12 months, operating cash flow was -112.16M and capital expenditures -143K, giving a free cash flow of -112.3M.
| Operating Cash Flow | -112.16M |
| Capital Expenditures | -143K |
| Free Cash Flow | -112.3M |
| FCF Per Share | -0.93 |
Margins
Gross margin is 90.27%, with operating and profit margins of -65.33% and -71.25%.
| Gross Margin | 90.27% |
| Operating Margin | -65.33% |
| Pretax Margin | -70.92% |
| Profit Margin | -71.25% |
| EBITDA Margin | -55.78% |
| EBIT Margin | -65.33% |
| FCF Margin | -57.14% |
Dividends & Yields
ARQT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -7.37% |
| FCF Yield | -6.02% |
Analyst Forecast
The average price target for ARQT is $19.5, which is 24% higher than the current price. The consensus rating is "Buy".
| Price Target | $19.5 |
| Price Target Difference | 24% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 1.92 |
| Piotroski F-Score | 4 |